Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Image: cover of this week's Barron's Magazine
"Gene Therapy Is Nearing a Major Breakthrough: Therapies that replace faulty genes with healthy ones to cure deadly diseases are generating exciting lab results. How to invest in a hot sector," by Barron's Andrew Barry:
"The goal of replacement gene therapy is to replace faulty genes with normal ones, in the hope of producing significant benefits or even cures. The process involves packaging healthy genes into neutered viruses, ... which then act as vectors delivered in a single dose either into the bloodstream or .. where the disease is."
Why it matters: "The first regulatory approval for this technology could come [from the FDA] as soon as January ... Other approvals could follow, igniting even greater interest in the field — and in the shares of several biotech companies making impressive headway in clinical trials."Free link for Axios readers. With graphic, "How replacement gene therapy works."
P.S. "Dow 1,000,000: Warren Buffett predicts that the benchmark will hit that number by 2117." (It closed yesterday at 22,000.) Free link for Axios readers.